Dorsey Wright & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Dorsey Wright & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.83M	Sell	53,902 -21,661	-29%	-$721K	0.31%	74
2026 Q1	$2.28M	Buy	75,563 +23,030	+44%	+$741K	0.28%	85
2025 Q4	$1.64M	Buy	+52,533	New	+$1.29M	0.35%	86
2025 Q2	–	Sell	-117,572	Closed	-$1.81M	–	155
2025 Q1	$1.81M	Sell	117,572 -13,315	-10%	-$238K	0.46%	94
2024 Q4	$2.88M	Sell	130,887 -37,975	-22%	-$691K	0.69%	59
2024 Q3	$3.04M	Buy	+168,862	New	+$2.96M	0.72%	61

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Dorsey Wright & Associates's TEVA Position: Q2 2026 in Review

Dorsey Wright & Associates reduced its Teva Pharmaceuticals (TEVA) stake by 29% in Q2 2026, selling an estimated $721K and leaving 53,902 shares worth $1.83M. The position accounts for 0.31% of the portfolio, ranked #74.

Dorsey Wright & Associates first reported a position in TEVA in Q3 2024 and has held it in 6 quarters since. The position peaked at $3.04M in Q3 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Dorsey Wright & Associates held 53,902 shares of Teva Pharmaceuticals worth $1.83M as of Q2 2026.
Dorsey Wright & Associates sold 21,661 Teva Pharmaceuticals shares in Q2 2026, an estimated $721K.
Teva Pharmaceuticals made up 0.31% of Dorsey Wright & Associates's portfolio in Q2 2026, its #74 holding.
Dorsey Wright & Associates first reported a position in Teva Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
Dorsey Wright & Associates's Teva Pharmaceuticals position peaked at $3.04M in Q3 2024.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Dorsey Wright & Associates's 13F filing for Q2 2026, filed 6 Aug 2026.